Lotus Eye Hospital and Institute Beheer
Beheer criteriumcontroles 4/4
De CEO Lotus Eye Hospital and Institute is Kuttapalayam Ramalingam, benoemd in Aug2020, heeft een ambtstermijn van 4.25 jaar. bezit rechtstreeks 1.43% van de aandelen van het bedrijf, ter waarde ₹ 19.07M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.2 jaar en 3.8 jaar.
Belangrijke informatie
Kuttapalayam Ramalingam
Algemeen directeur
₹1.2m
Totale compensatie
| Percentage CEO-salaris | n/a |
| Dienstverband CEO | 4.3yrs |
| Eigendom CEO | 1.4% |
| Management gemiddelde ambtstermijn | 4.2yrs |
| Gemiddelde ambtstermijn bestuur | 3.8yrs |
Recente managementupdates
Recent updates
Optimistic Investors Push Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) Shares Up 25% But Growth Is Lacking
Aug 21
Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) Price Is Out Of Tune With Earnings
Jan 24Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50
Sep 08We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease
Jul 15Here's Why Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Has Caught The Eye Of Investors
Apr 07We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease
Oct 08Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50
Sep 02If EPS Growth Is Important To You, Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Presents An Opportunity
Jun 17MD & Whole Time Director Sangeetha Sundaramoorthy Just Bought 2.8% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)
Mar 11Chief Executive Officer K. Ramalingam Just Bought 122% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)
Dec 30Insider Buying: The Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) MD & Whole Time Director Just Bought 2.8% More Shares
Nov 20The Chief Executive Officer of Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE), K. Ramalingam, Just Bought 17% More Shares
Sep 21Why Investors Shouldn't Be Surprised By Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) P/E
Aug 27
Should You Take Comfort From Insider Transactions At Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)?
Aug 03Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) P/E Isn't Throwing Up Surprises
Jul 06CEO
Kuttapalayam Ramalingam (74 yo)
4.3yrs
Tenure
₹1,200,000
Compensatie
Dr. Kuttapalayam Songappan Ramalingam, M.D., serves as an Executive Director at Lotus Eye Hospital and Institute Limited since February 10, 2021. Dr. Ramalingam serves as Chief Executive Officer at Lotus E...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Executive Director | 4.3yrs | ₹1.20m | 1.43% ₹ 19.1m | |
| Chief Financial Officer | 2.5yrs | ₹1.70m | geen gegevens | |
| Company Secretary & Compliance Officer | 2.8yrs | ₹1.08m | geen gegevens | |
| MD & Director | 4.2yrs | ₹3.09m | 18.84% ₹ 250.4m | |
| Vice President of Administration | 6.5yrs | geen gegevens | 0% ₹ 0 |
4.2yrs
Gemiddelde duur
67yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van LOTUSEYE wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.2 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Executive Director | 3.8yrs | ₹1.20m | 1.43% ₹ 19.1m | |
| MD & Director | 5yrs | ₹3.09m | 18.84% ₹ 250.4m | |
| Vice President of Administration | 4.8yrs | geen gegevens | 0% ₹ 0 | |
| Chairman of the Board | 8.5yrs | ₹150.00k | 18.78% ₹ 249.6m | |
| Independent Director | 3.8yrs | ₹200.00k | geen gegevens | |
| Independent Non-Executive Director | 1.9yrs | ₹200.00k | geen gegevens | |
| Independent Non-Executive Director | 1.8yrs | ₹175.00k | geen gegevens |
3.8yrs
Gemiddelde duur
61yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van LOTUSEYE wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).